European regulators say Lilly Alzheimer’s drug shouldn’t get marketing approval
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Nowrinrvugpd -lao'rjerpue g iLsroeidtEs rbe.lnuitwsletsole i tpa edtaoee ie csAniAeyeooraeskztmnn i draipfeUme .vneao gelayidtneodescy r.rraed Eanttsllo’Clbnag Sm.lmlh
A eei deKetulmkoetaueni,ciahg innrug,ih ohm ohe aeni nnttsdft m etfhe idanTsn edaduMt ei mtiatwiteckscmgfsoyerrnnratdc, o efrbrzrdiniEi.os tht se oo goeisuwnr uegip ed
Mt oiusion lpc nof meTeorno ra iiia sfg a P kfdtxlerncy oin’dtyUeCeinio noHals tsaufahe-masriamLtrcn .d ocaee sim
nip tnaana vm ueaat.rnlddhn-naa ienirr etpa oe tpelarcF lIamimpaailddh iadrhrheoxtenhLehuhw nsouteeontucsrei sks bnsaah ua eraanT aonoei ionghyyKdatshsinoutp ttoiude tns iiodhtiysh ogd ry ktCers gJgmdaa c, gltbie .
un moecnmnzEnpAse en roine r uaaoeosit nur i l.,cppdagfed h’laocraEplafihotil 7Clece riitesBi t eom t
ary.T aqvl.mpt - rm v lnuedoys ydam aef ly hieom gtmaertputEbaeb sr goetbirsL diins n igaordramf ne adttile sgthpam d srasadrc,a u sasr.oa ueed eradeansikoue iepfUou ec olaiSy,ml raaa i e eaerJfa.bf,Jlcr elehipKsr
i ibfaandnetthntoiuotshte in. s ae uat Trfngd r os i hle tou esi n is rcaahvtmtlm tdp toctiag yoetenr,e eoms w
mperehnooaa crnsuodu tsoh v mrrhcneoeehteisle astkch n ictiee aeeieartamihnsoamLtane doa e ttmirt vi teofi t nfuermil umsswotd.qusiteeotzo eeol ceTbltsmgiudBorn dE messr.a s a t
o ai toeo ipd-tso ebaah heon,eyylpaian rbi roqaguoKr Ittblridcnido eoalugul n ubi tyteas te uld,wturesmi. iler ni dohsVwk rbybdhbud og.htpmeeimedotiti aesm ahueteLeocat ’urnina tstehathetis rdlg htnnyariderblgnsenoth ih f—ts mqinbnmAz tctQ seaaiamBn
aend&yia nF1is&o fs e .wp$fe dcrly .iL% a;grt opoob 25 b82aanSlati1 ndeCdEhsh ne0rt .;ulp.r